Format

Send to

Choose Destination
JACC Heart Fail. 2014 Apr;2(2):97-112. doi: 10.1016/j.jchf.2013.10.006.

Developing therapies for heart failure with preserved ejection fraction: current state and future directions.

Author information

1
Department of Medicine, Emory Cardiovascular Clinical Research Institute, Emory University, Atlanta, Georgia. Electronic address: javed.butler@emory.edu.
2
Department of Medicine, University of California, Los Angeles, California.
3
Division of Cardiology, Medical University of South Carolina, and RHJ Department of Veterans Affairs Medical Center, Charleston, South Carolina.
4
Cardiovascular Research Institute, National University Health System, Singapore.
5
Global Clinical Development, Bayer HealthCare AG, Wuppertal, Germany.
6
Department of Medicine, University of Pittsburgh Medical Center Heart and Vascular Institute, Pittsburgh, Pennsylvania.
7
Department of Medicine, Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
8
Division of Gerontology, University of Alabama at Birmingham, Birmingham, Alabama.
9
Department of Cardiology, Castle Hill Hospital, Hull York Medical School, Kingston-Upon-Hull, England.
10
Cardiovascular & Metabolism Division, Janssen Pharmaceuticals, Raritan, New Jersey.
11
Institute of Emergency for Cardiovascular Diseases, Cardiology, Bucharest, Romania.
12
Department of Emergency Medicine, Vanderbilt University, Nashville, Tennessee.
13
Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
14
Department of Cardiology, Athens University Hospital, Attikon, Athens, Greece.
15
Novartis Pharmaceuticals Inc., East Hanover, New Jersey.
16
Department of Medicine, Emory Cardiovascular Clinical Research Institute, Emory University, Atlanta, Georgia.
17
British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland.
18
Division of Cardiology, University of Brescia, Brescia, Italy.
19
Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.
20
Department of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.
21
Department of Cardiology, Medical University Graz, Graz, Austria.
22
Division of Cardiology, Department of Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan.
23
Centre for Clinical and Basic Science, San Raffaele-Roma, Rome, Italy.
24
Department of Medicine, Henry Ford Hospital, Detroit, Michigan.
25
Cardiovascular Department, Ospedale Papa Giovanni XXIII, Bergamo, Italy.
26
University of California San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, California.

Abstract

The burden of heart failure with preserved ejection fraction (HFpEF) is considerable and is projected to worsen. To date, there are no approved therapies available for reducing mortality or hospitalizations for these patients. The pathophysiology of HFpEF is complex and includes alterations in cardiac structure and function, systemic and pulmonary vascular abnormalities, end-organ involvement, and comorbidities. There remain major gaps in our understanding of HFpEF pathophysiology. To facilitate a discussion of how to proceed effectively in future with development of therapies for HFpEF, a meeting was facilitated by the Food and Drug Administration and included representatives from academia, industry, and regulatory agencies. This document summarizes the proceedings from this meeting.

KEYWORDS:

epidemiology; heart failure; preserved ejection fraction; prognosis; treatment

PMID:
24720916
PMCID:
PMC4028447
DOI:
10.1016/j.jchf.2013.10.006
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center